Cargando…

Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template

The RNA-dependent RNA polymerase of the severe acute respiratory syndrome coronavirus 2 is an important target in current drug development efforts for the treatment of coronavirus disease 2019. Molnupiravir is a broad-spectrum antiviral that is an orally bioavailable prodrug of the nucleoside analog...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gordon, Calvin J., Tchesnokov, Egor P., Schinazi, Raymond F., Götte, Matthias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Biochemistry and Molecular Biology 2021
Materias:	Accelerated Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8110631/ https://www.ncbi.nlm.nih.gov/pubmed/33989635 http://dx.doi.org/10.1016/j.jbc.2021.100770

Ejemplares similares

Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis
por: Kabinger, Florian, et al.
Publicado: (2021)

Decoding molnupiravir-induced mutagenesis in SARS-CoV-2
por: Menéndez-Arias, Luis
Publicado: (2021)

Template-dependent inhibition of coronavirus RNA-dependent RNA polymerase by remdesivir reveals a second mechanism of action
por: Tchesnokov, Egor P., et al.
Publicado: (2020)

Correction: Template-dependent inhibition of coronavirus RNA-dependent RNA polymerase by remdesivir reveals a second mechanism of action
por: Tchesnokov, Egor P., et al.
Publicado: (2021)

Efficient incorporation and template-dependent polymerase inhibition are major determinants for the broad-spectrum antiviral activity of remdesivir
por: Gordon, Calvin J., et al.
Publicado: (2021)

Inhibition of viral RNA-dependent RNA polymerases with clinically relevant nucleotide analogs
por: Maheden, Kieran, et al.
Publicado: (2021)

N4-hydroxycytidine, the active compound of Molnupiravir, promotes SARS-CoV-2 mutagenesis and escape from a neutralizing nanobody
por: Zibat, Arne, et al.
Publicado: (2023)

Molnupiravir Does Not Induce Mutagenesis in Host Lung Cells during SARS-CoV-2 Treatment
por: Githaka, John Maringa
Publicado: (2022)

The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus
por: Gordon, Calvin J., et al.
Publicado: (2020)

Evolution of naturally arising SARS-CoV-2 defective interfering particles
por: Girgis, Samer, et al.
Publicado: (2022)

The active form of the influenza cap-snatching endonuclease inhibitor baloxavir marboxil is a tight binding inhibitor
por: Todd, Brendan, et al.
Publicado: (2021)

The Nucleoside/Nucleotide Analogs Tenofovir and Emtricitabine Are Inactive against SARS-CoV-2
por: Feng, Joy Y., et al.
Publicado: (2022)

Molnupiravir’s mechanism of action drives “error catastrophe” in SARS-CoV-2: A therapeutic strategy that leads to lethal mutagenesis of the virus
por: Chatterjee, Srijan, et al.
Publicado: (2023)

Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency
por: Gordon, Calvin J., et al.
Publicado: (2020)

Safety and efficacy of molnupiravir in SARS‐CoV‐2‐infected patients: A real‐life experience
por: De Vito, Andrea, et al.
Publicado: (2022)

Recombinant RNA-Dependent RNA Polymerase Complex of Ebola Virus
por: Tchesnokov, Egor P., et al.
Publicado: (2018)

Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir
por: Tchesnokov, Egor P., et al.
Publicado: (2019)

Mutations in the SARS-CoV-2 RNA dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms
por: Stevens, Laura J., et al.
Publicado: (2022)

Real-Life Experience of Molnupiravir in Hospitalized Patients Who Developed SARS-CoV2-Infection: Preliminary Results from CORACLE Registry
por: Lupia, Tommaso, et al.
Publicado: (2022)

Independent inhibition of the polymerase and deubiquitinase activities of the Crimean-Congo Hemorrhagic Fever Virus full-length L-protein
por: Tchesnokov, Egor P., et al.
Publicado: (2020)

Molnupiravir—A Novel Oral Anti-SARS-CoV-2 Agent
por: Lee, Ching-Chi, et al.
Publicado: (2021)

Molnupiravir for SARS-CoV-2 infection: Public health and policy implications
por: Gray, Edward J., et al.
Publicado: (2023)

Molnupiravir: A Versatile Prodrug against SARS-CoV-2 Variants
por: Teli, Divya, et al.
Publicado: (2023)

Antiviral Efficacy of Molnupiravir for COVID-19 Treatment
por: Bai, Yuan, et al.
Publicado: (2022)

SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination
por: Li, Pengfei, et al.
Publicado: (2022)

Molnupiravir inhibits SARS-CoV-2 variants including Omicron in the hamster model
por: Rosenke, Kyle, et al.
Publicado: (2022)

A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes
por: Sanderson, Theo, et al.
Publicado: (2023)

Real-World Use of Molnupiravir in the Treatment of Outpatients with SARS-CoV-2 Infection—A Patient Profile Based on the Experience of a Tertiary Infectious Disease Center
por: Streinu-Cercel, Anca, et al.
Publicado: (2022)

β-d-N(4)-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells
por: Zhou, Shuntai, et al.
Publicado: (2021)

Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected mice
por: Jeong, Ju Hwan, et al.
Publicado: (2022)

Combined molnupiravir-nirmatrelvir treatment improves the inhibitory effect on SARS-CoV-2 in macaques
por: Rosenke, Kyle, et al.
Publicado: (2023)

Combination Therapy with UV-4B and Molnupiravir Enhances SARS-CoV-2 Suppression
por: Franco, Evelyn J., et al.
Publicado: (2023)

Migrating bubble synthesis promotes mutagenesis through lesions in its template
por: Osia, Beth, et al.
Publicado: (2022)

Inhibitors of dihydroorotate dehydrogenase cooperate with molnupiravir and N4-hydroxycytidine to suppress SARS-CoV-2 replication
por: Stegmann, Kim M., et al.
Publicado: (2022)

Genomic characteristics and viral load dynamics of a SARS-CoV-2 Omicron BA.2.2 variant from a hospitalized patient treated with molnupiravir
por: Chan, Wai Sing, et al.
Publicado: (2022)

Duplex formation between the template and the nascent strand in the transcription-regulating sequences is associated with the site of template switching in SARS – CoV-2
por: D’Souza, Aaron R., et al.
Publicado: (2021)

Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance
por: Flisiak, Robert, et al.
Publicado: (2022)

Editorial: Rebound COVID-19 and Cessation of Antiviral Treatment for SARS-CoV-2 with Paxlovid and Molnupiravir
por: Parums, Dinah V.
Publicado: (2022)

153. Molnupiravir Exhibits a High Barrier to the Development of SARS-CoV-2 Resistance in vitro
por: Strizki, Julie, et al.
Publicado: (2022)

Evaluation of molnupiravir (EIDD-2801) efficacy against SARS-CoV-2 in the rhesus macaque model
por: Johnson, Dylan M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5kob4c2adkc3h80damm1rhb0me